Interferon Alfa-2b, Recombinant

Identification

Name
Interferon Alfa-2b, Recombinant
Accession Number
DB00105  (BTD00066, BIOD00066, DB05600)
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Interferons
Description

Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.

Protein structure
Db00105
Protein chemical formula
C860H1353N229O255S9
Protein average weight
19271.0 Da
Sequences
>DB00105 sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Download FASTA Format
Synonyms
  • Interferon alfa-2b
  • Interferon α-2b
  • Intron (Interferon α2b)
  • Intron A (Interferon α2b)
  • rIFN-alpha-2b
External IDs
99210-65-8 / Sch 30500 / YM 14090
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Intron AInjection, solution11.6 ug/.5mLIntramuscular; SubcutaneousMerck Sharp & Dohme Limited1986-06-04Not applicableUs
Intron ASolution6000000 unitIntramuscular; Intravenous; SubcutaneousMerck Ltd.1998-12-10Not applicableCanada
Intron AKitMerck Sharp & Dohme Limited2014-08-11Not applicableUs
Intron ALiquid15000000 unitSubcutaneousMerck Ltd.1999-09-23Not applicableCanada
Intron AKitMerck Sharp & Dohme Limited1986-06-042017-12-22Us
Intron ALiquid50000000 unitSubcutaneousMerck Ltd.1999-09-23Not applicableCanada
Intron AInjection, solution19.2 ug/.5mLIntralesional; Intramuscular; SubcutaneousMerck Sharp & Dohme Limited1986-06-04Not applicableUs
Intron ASolution10000000 unitIntramuscular; Intravenous; SubcutaneousMerck Ltd.1998-12-10Not applicableCanada
Intron AKitMerck Sharp & Dohme Limited1986-06-042017-12-22Us
Intron AKitMerck Sharp & Dohme Limited2014-08-11Not applicableUs
International/Other Brands
Intron A / Locteron
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Intron AInterferon Alfa-2b, Recombinant (10000000 unit) + Water (1 ml)Liquid; Powder, for solutionIntralesional; Intramuscular; Intravenous; SubcutaneousMerck Ltd.1997-03-12Not applicableCanada
Intron AInterferon Alfa-2b, Recombinant (18 miu) + Water (1 ml)Kit; Liquid; Powder, for solutionIntralesional; Intramuscular; Intravenous; SubcutaneousMerck Ltd.1998-03-11Not applicableCanada
Intron A - Kit (pws+diluent) 3000000iu/vialInterferon Alfa-2b, Recombinant (3000000 unit) + Water (1 ml)Liquid; Powder, for solutionIntralesional; Intramuscular; SubcutaneousSchering Plough (Brinny) Co.1997-04-082000-07-11Canada
Intron A - Kit (pws+diluent) 5000000iu/vialInterferon Alfa-2b, Recombinant (5000000 unit) + Water (1 ml)Liquid; Powder, for solutionIntralesional; Intramuscular; SubcutaneousSchering Plough (Brinny) Co.1998-12-312000-07-11Canada
Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Interferon Alfa-2b, Recombinant (6000000 unit) + Ribavirin (200 mg)Capsule; Kit; LiquidOral; SubcutaneousSchering Plough1999-03-312004-10-27Canada
Rebetron Solution (albumin (human) Free) (18 Miu Multi-dose Pen / 200mg Capsules)Interferon Alfa-2b, Recombinant (15000000 unit) + Ribavirin (200 mg)Capsule; Kit; LiquidOral; SubcutaneousSchering Plough1999-12-232004-10-27Canada
Categories
UNII
43K1W2T1M6
CAS number
98530-12-2

Pharmacology

Indication

For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.

Structured Indications
Pharmacodynamics

Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.

Mechanism of action

Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.

TargetActionsOrganism
AInterferon alpha/beta receptor 2
binder
Human
AInterferon alpha/beta receptor 1
binder
Human
Absorption

Absorption is high (greater than 80%) when administered intramuscularly or subcutaneously.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

The elimination half-life following both intramuscular and subcutaneous injections was approximately 2 to 3 hours. The elimination half-life was approximately 2 hours following intravenous injection.

Clearance
Not Available
Toxicity

There is limited experience with overdosage. Postmarketing surveillance includes reports of patients receiving a single dose as great as 10 times the recommended dose. In general, the primary effects of an overdose are consistent with the effects seen with therapeutic doses of interferon alfa-2b. Hepatic enzyme abnormalities, renal failure, hemorrhage, and myocardial infarction have been reported with single administration overdoses and/or with longer durations of treatment than prescribed. Toxic effects after ingestion of interferon alfa-2b are not expected because interferons are poorly absorbed orally.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Aldesleukin.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon Alfa-2b, Recombinant.Experimental, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Interferon Alfa-2b, Recombinant.Approved, Investigational, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
GitoformateGitoformate may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental
MethadoneThe serum concentration of Methadone can be increased when it is combined with Interferon Alfa-2b, Recombinant.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Experimental
RibavirinThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Ribavirin.Approved
TelbivudineThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Telbivudine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Interferon Alfa-2b, Recombinant.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Zidovudine.Approved
Food Interactions
  • Avoid alcohol.

References

General References
  1. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushan TL, Walter MR: Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography. Structure. 1996 Dec 15;4(12):1453-63. [PubMed:8994971]
External Links
UniProt
P01563
PubChem Substance
46507075
Therapeutic Targets Database
DAP001285
PharmGKB
PA164783990
RxList
RxList Drug Page
ATC Codes
L03AB05 — Interferon alfa-2b
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
  • 08:18.20 — Interferons
FDA label
Download (3.52 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMelanoma1
1Active Not RecruitingTreatmentSolid Cancers1
1CompletedNot AvailableHepatitis C Viral Infection1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentBladder Cancers / Urethral Cancer1
1CompletedTreatmentCancer, Advanced / Tumors, Solid1
1CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
1CompletedTreatmentMelanoma3
1CompletedTreatmentRecurrent Melanoma / Recurrent Renal Cell Cancer / Stage III Melanoma / Stage IV Melanoma / Stage IV Renal Cell Cancer1
1, 2Active Not RecruitingTreatmentMelanoma1
1, 2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Genotype 1 / Relapses / Treatment-Experienced Patients1
1, 2CompletedTreatmentMelanoma1
1, 2CompletedTreatmentRecurrent Ovarian Cancer1
1, 2Not Yet RecruitingTreatmentBreast Neoplasm Female / Malignant Neoplasm of Female Breast1
1, 2RecruitingTreatmentBreastcancer / Neoplasms, Breast1
1, 2RecruitingTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas Metastatic to Peritoneal Surface / Malignant Peritoneal Mesothelioma / Peritoneal Carcinomatosis1
1, 2TerminatedTreatmentMalignant Lymphomas / Precancerous/Nonmalignant Condition1
1, 2TerminatedTreatmentRenal Cell Adenocarcinoma1
1, 2WithdrawnTreatmentMelanoma1
2Active Not RecruitingTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Iris Melanoma / Recurrent Intraocular Melanoma1
2Active Not RecruitingTreatmentCutaneous Melanoma / Metastatic Melanoma1
2Active Not RecruitingTreatmentRecurrent Melanoma / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
2CompletedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer1
2CompletedTreatmentHepatitis C Viral Infection1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentRenal Cell Adenocarcinoma / Stage IV Renal Cell Cancer1
2RecruitingTreatmentMucosal Melanoma1
2TerminatedTreatmentClear Cell Renal Cell Carcinoma / Papillary Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentMycosis Fungoides (MF) / Neoplasms, Hematologic / T-Cell Lymphomas1
2TerminatedTreatmentRecurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2Unknown StatusTreatmentMetastatic Renal Cell Carcinoma1
2WithdrawnTreatmentCancer, Advanced / Tumors, Solid1
2WithdrawnTreatmentMalignant Melanoma / Melanoma1
2, 3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
3Active Not RecruitingTreatmentMetastatic Non-Cutaneous Melanoma / Non-Cutaneous Melanoma / Recurrent Melanoma of the Skin / Recurrent Non-Cutaneous Melanoma / Stage III Cutaneous Melanoma AJCC v7 / Stage III Mucosal Melanoma of the Head and Neck / Stage III Mucosal Melanoma of the Head and Neck AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma / Stage IVA Mucosal Melanoma of the Head and Neck / Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7 / Stage IVB Mucosal Melanoma of the Head and Neck / Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7 / Stage IVC Mucosal Melanoma of the Head and Neck / Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7 / Stages III Skin Melanoma1
3Active Not RecruitingTreatmentNeuroendocrine Carcinomas1
3Active Not RecruitingTreatmentRecurrent Melanoma / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Skin Melanoma1
3CompletedTreatmentLeukemia,Myeloid, Chronic1
3CompletedTreatmentMalignant Melanoma / Recurrent Melanoma1
3CompletedTreatmentMelanoma / Neoplasms Metastasis1
3CompletedTreatmentMelanoma / Skin Cancers1
3CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3RecruitingTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Glioblastomas1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentMelanoma (Skin)1
3WithdrawnTreatmentGastro-intestinal Neuroendocrine Tumors1
3WithdrawnTreatmentHypertrophic Scars / Minor burns1
4CompletedTreatmentConjunctival Intraepithelial Neoplasia / Corneal Intraepithelial Neoplasia1
4CompletedTreatmentHepatitis B,Chronic1
4RecruitingTreatmentLymphoma, T-Cell, Cutaneous / Mycosis Fungoides (MF)1
Not AvailableActive Not RecruitingTreatmentStage IA Skin Melanoma / Stage IB Skin Melanoma / Stage IIA Skin Melanoma / Stage IIB Skin Melanoma / Stage IIC Skin Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
Not AvailableCompletedNot AvailableMelanoma2
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Progressive Multifocal Leukoencephalopathy1
Not AvailableRecruitingTreatmentLeukemias1
Not AvailableTerminatedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntralesional; Intramuscular; Subcutaneous19.2 ug/.5mL
Injection, solutionIntramuscular; Subcutaneous11.6 ug/.5mL
Kit
Kit; liquid; powder, for solutionIntralesional; Intramuscular; Intravenous; Subcutaneous
LiquidSubcutaneous15000000 unit
LiquidSubcutaneous25000000 unit
LiquidSubcutaneous50000000 unit
Liquid; powder, for solutionIntralesional; Intramuscular; Intravenous; Subcutaneous
SolutionIntramuscular; Intravenous; Subcutaneous10000000 unit
SolutionIntramuscular; Intravenous; Subcutaneous6000000 unit
Liquid; powder, for solutionIntralesional; Intramuscular; Subcutaneous
LiquidIntralesional; Intramuscular; Subcutaneous5000000 unit
LiquidSubcutaneous10000000 unit
LiquidSubcutaneous3000000 unit
LiquidSubcutaneous5000000 unit
Capsule; kit; liquidOral; Subcutaneous
Prices
Unit descriptionCostUnit
Intron-A 10000000 unit/0.2ml Kit (each Box Contains One 6 Dose 1.5ml Pen)1110.84USD box
Intron a 10 million unit pen1068.12USD pen
Intron-A 5000000 unit/0.2ml Kit Box683.34USD box
Intron a 5 million unit/ml pen657.06USD pen
Intron a 3 million unit/ml pen394.21USD pen
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341567No2008-02-192025-02-19Canada
CA2201749No1999-06-152015-10-10Canada

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °CBeldarrain, A. et al., Biochemistry 38:7865-7873 (1999)
hydrophobicity-0.339Not Available
isoelectric point5.99Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are direc...
Gene Name
IFNAR2
Uniprot ID
P48551
Uniprot Name
Interferon alpha/beta receptor 2
Molecular Weight
57758.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Eid P, Tovey MG: Characterization of a domain of a human type I interferon receptor protein involved in ligand binding. J Interferon Cytokine Res. 1995 Mar;15(3):205-11. [PubMed:7584665]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JA...
Gene Name
IFNAR1
Uniprot ID
P17181
Uniprot Name
Interferon alpha/beta receptor 1
Molecular Weight
63524.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Khine AA, Lingwood CA: Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity. J Cell Physiol. 2000 Jan;182(1):97-108. [PubMed:10567921]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da

Drug created on June 13, 2005 07:24 / Updated on January 14, 2018 10:04